Table 1 Baseline Demographics and Migraine Characteristics
N = 395 | |
|---|---|
Gender (female) | 85.1% |
Age (mean, years ± SD) | 46.7 ± 12.6 |
Aura | 28.6% |
Migraine duration (mean, years ± SD) | 28.6 ± 15.0 |
Chronification time (mean, years ± SD) | 10.5 ± 9.9 |
Headache frequency (days/month ± SD) | 26.5 ± 5.2 |
Moderate-Severe headache frequency (days/month ± SD) | 12.7 ± 7.5 |
Moderate-Severe headache monthly rate (% ± SD) | 49.0 ± 27.6 |
Acute treatment (% of use) | 95.7% |
NSAIDs | 54.6% |
Triptans | 46.1% |
Other analgesics | 36.3% |
Analgesic use (mean, tablets/month ± SD) | 42.2 ± 42.4 |
Daily use of analgesic | 38.7% |
Medication overuse | 61.3% |
Stable concomitant preventive treatment (%) | 77.0% |
Neuromodulators | 39.2% |
Betablockers | 14.9% |
Antidepressants | 61.5% |
Others | 10.6% |
MIDAS disability category | |
None | 5.6% |
Mild | 4.8% |
Moderate | 6.8% |
Severe | 82.8% |
MIDAS score (mean ± SD) | 82.6 ± 64.6 |